As shown in   the top retargets predicted by the linear retrofitting model are all medically plausible.
the model confidently predicts that Kenalog would treat contact dermatitis, an effect also found in a clinical trial (Usatine and Riojas, 2010).The second most confident prediction of drug retargets was that Kenalog can treat pemphigus, which is indicated on Kenalog's drug label, 6 but was not previously included in the knowledge graph.